Historical Valuation
Mereo BioPharma Group PLC (MREO) is now in the Fair zone, suggesting that its current forward PS ratio of 4.64 is considered Fairly compared with the five-year average of -82.88. The fair price of Mereo BioPharma Group PLC (MREO) is between 0.04 to 1.29 according to relative valuation methord.
Relative Value
Fair Zone
0.04-1.29
Current Price：0.38
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Mereo BioPharma Group PLC (MREO) has a current Price-to-Book (P/B) ratio of 1.74. Compared to its 3-year average P/B ratio of 6.07 , the current P/B ratio is approximately -71.30% higher. Relative to its 5-year average P/B ratio of 3.78, the current P/B ratio is about -53.92% higher. Mereo BioPharma Group PLC (MREO) has a Forward Free Cash Flow (FCF) yield of approximately -40.30%. Compared to its 3-year average FCF yield of -14.53%, the current FCF yield is approximately 177.26% lower. Relative to its 5-year average FCF yield of -16.04% , the current FCF yield is about 151.28% lower.
P/B
Median3y
6.07
Median5y
3.78
FCF Yield
Median3y
-14.53
Median5y
-16.04
Competitors Valuation Multiple
AI Analysis for MREO
The average P/S ratio for MREO competitors is 0.77, providing a benchmark for relative valuation. Mereo BioPharma Group PLC Corp (MREO.O) exhibits a P/S ratio of 4.64, which is 500% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MREO
1Y
3Y
5Y
Market capitalization of MREO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MREO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MREO currently overvalued or undervalued?
Mereo BioPharma Group PLC (MREO) is now in the Fair zone, suggesting that its current forward PS ratio of 4.64 is considered Fairly compared with the five-year average of -82.88. The fair price of Mereo BioPharma Group PLC (MREO) is between 0.04 to 1.29 according to relative valuation methord.
What is Mereo BioPharma Group PLC (MREO) fair value?
MREO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Mereo BioPharma Group PLC (MREO) is between 0.04 to 1.29 according to relative valuation methord.
How does MREO's valuation metrics compare to the industry average?
The average P/S ratio for MREO's competitors is 0.77, providing a benchmark for relative valuation. Mereo BioPharma Group PLC Corp (MREO) exhibits a P/S ratio of 4.64, which is 500.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Mereo BioPharma Group PLC (MREO) as of Jan 09 2026?
As of Jan 09 2026, Mereo BioPharma Group PLC (MREO) has a P/B ratio of 1.74. This indicates that the market values MREO at 1.74 times its book value.
What is the current FCF Yield for Mereo BioPharma Group PLC (MREO) as of Jan 09 2026?
As of Jan 09 2026, Mereo BioPharma Group PLC (MREO) has a FCF Yield of -40.30%. This means that for every dollar of Mereo BioPharma Group PLC’s market capitalization, the company generates -40.30 cents in free cash flow.
What is the current Forward P/E ratio for Mereo BioPharma Group PLC (MREO) as of Jan 09 2026?
As of Jan 09 2026, Mereo BioPharma Group PLC (MREO) has a Forward P/E ratio of -15.80. This means the market is willing to pay $-15.80 for every dollar of Mereo BioPharma Group PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Mereo BioPharma Group PLC (MREO) as of Jan 09 2026?
As of Jan 09 2026, Mereo BioPharma Group PLC (MREO) has a Forward P/S ratio of 4.64. This means the market is valuing MREO at $4.64 for every dollar of expected revenue over the next 12 months.